Skip to main content
OpenTrials
Completed

NCT Number: NCT04499482

Safety and Tolerability of Soy Fiber

This is a dose escalation trial in the elderly with obesity to determine the maximum tolerated dose of a novel dietary fiber from whole young soy pods (soy) delivered in foods.

Completed

Looking for future studies?

Notify Me

Key information

Age range

70 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

About this study

The tolerability to 10 g, 20 g, and 30 g of soy will be tested. At each dose, eight subjects will incorporate the foods containing soy into their usual diet for one week. The tolerability to each dose will be evaluated and fecal short chain fatty acids will be measured as a biomarker of compliance. Subjects who satisfy the eligibility criteria and express willingness to consume the study foods will be enrolled.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (70 - 85 years).
  • Body mass index between 30 and 40 kg/m2.
  • No evidence of diabetes (fasting blood sugar <126 mg/dL).
  • No evidence of dementia (MMSE score > 25).
  • No evidence of depression. (Geriatric Depression Scale-15 [GDS-15] < 6.
  • Are weight stable (< 3 kg weight change in the past three months).

Exclusion criteria

  • Have type 1 or type 2 diabetes currently being treated by medication.
  • Report clinically significant gastrointestinal malabsorption syndromes such as chronic diarrhea, or celiac disease.
  • Are being treated with medications that have a significant effect on insulin resistance, obesity, and metabolic rate, or medications that significantly increase body weight such as antidepressants, second-generation antipsychotics, systemic glucocorticoids, and adrenergic blockers or stimulators (unless the dose and body weight have been stable for six months).
  • Have serum triglyceride concentrations > 400 mg/dl.
  • Clinically significant abnormal laboratory markers (as determined by the medical investigator).
  • Subjects with anticipated surgery during the study period.
  • Subjects with a reported history of substance abuse or alcoholism or significant psychiatric disorder that would interfere with the ability to complete the study.
  • Subjects who are current smokers or have smoked within the previous three months. Smoking is not permitted during the study.
  • Subjects who are unable to provide a baseline blood or fecal sample or if they have any condition that impedes testing of the study hypothesis or makes it unsafe to consume the food being tested in the study (determined by the investigative team).
  • Women on hormone replacement therapy unless weight has been stable over the last six months.

Treatment and study plan

Food

Other

Soy-fiber containing food

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events Following Each Dose of Soy

    Time frame: One week at each dose

    Dose safety will be investigated by compiling by treatment (e.g. 10 g dose, 20 g dose, 30 g dose) a list of adverse events such as frequency of headaches, nausea, vomiting. The study physician in consultation with the coordinator will review and determine safety

  2. 10 g Soy-related Gastrointestinal Symptoms

    Time frame: One week

    Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe.

  3. 20 g Soy-related Gastrointestinal Symptoms

    Time frame: One week

    Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe.

  4. 30 g Soy-related Gastrointestinal Symptoms

    Time frame: One week

    Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe.

  5. 10 g Soy-related Stool Frequency

    Time frame: One week

    Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week

  6. 20 g Soy-related Stool Frequency

    Time frame: One week

    Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week

  7. 30 g Soy-related Stool Frequency

    Time frame: One week

    Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week

  8. 10 Soy-related Stool Consistency

    Time frame: One week

    Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal.

  9. 20 g Soy-related Stool Consistency

    Time frame: One week

    Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal.

  10. 30 g Soy-related Stool Consistency

    Time frame: One week

    Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal.

Secondary outcomes

  1. 10 g Soy Intake Effect on Fecal Short Chain Fatty Acids

    Time frame: One week

    Measurement of fecal short chain fatty acids in response to intake of soy

  2. 20 g Soy Intake Effect on Fecal Short Chain Fatty Acids

    Time frame: One week

    Measurement of fecal short chain fatty acids in response to intake of soy

  3. 30 g Soy Intake Effect on Fecal Short Chain Fatty Acids

    Time frame: One week

    Measurement of fecal short chain fatty acids in response to intake of soy

Sponsors and collaborators

Lead sponsor

Pennington Biomedical Research Center

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Safety and Tolerability of Soy Fiber in the Elderly: A Dose Escalation Study

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 5, 2020
Registry last updated
May 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.